1800-272-662
Shopping Cart 0
countryflagAU
Login

Percheron Therapeutics Ltd

Healthcare AU PER

NoneAUD
-(-%)

Last update at 2026-03-06T06:45:01.985749Z

Day Range

--
LowHigh

52 Week Range

0.0060.01
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap7.61M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.42626M
  • Revenue TTM1.74M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 1.55M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -16.35187M -14.27122M -11.37983M -5.81181M -8.06064M
Minority interest - - - - -
Net income -14.92191M -11.91922M -11.37983M -5.83408M -8.06719M
Selling general administrative 5.71M 4.04M 3.05M 2.92M 3.56M
Selling and marketing expenses - - - - -
Gross profit -0.06798M -0.07942M - - -
Reconciled depreciation 0.07M 0.08M 0.10M 0.09M 0.10M
Ebit -16.33694M -11.91562M -13.34497M -7.61123M -8.68328M
Ebitda -16.26897M -11.83620M -13.24978M -7.52201M -8.57996M
Depreciation and amortization 0.07M 0.08M 0.10M 0.09M 0.10M
Non operating income net other - - - - -
Operating income -16.70804M -14.88012M -13.34497M -7.61123M -8.68328M
Other operating expenses 16.71M 14.88M 13.34M 7.61M 8.68M
Interest expense 0.01M 0.00360M - 0.02M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.37M 0.62M 0.38M 0.03M 0.00418M
Net interest income 0.36M 0.61M 0.38M 0.02M -0.00655M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.42996M -2.35200M -0.37677M 0.02M 0.00655M
Total revenue - - 0.38M 0.03M 0.00418M
Total operating expenses 16.64M 14.80M 13.34M 7.61M 8.68M
Cost of revenue 0.07M 0.08M - - -
Total other income expense net 0.36M 0.61M 1.59M 1.80M 0.62M
Discontinued operations - - - - -
Net income from continuing ops -14.92191M -11.91922M -11.37983M -5.81181M -8.06064M
Net income applicable to common shares - - -11.37983M -5.81181M -8.06064M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 12.44M 14.53M 12.84M 22.44M 7.00M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - 1.47M 0.53M 0.67M
Total liab 2.43M 5.17M 2.87M 1.30M 1.27M
Total stockholder equity 10.00M 9.36M 9.98M 21.14M 5.73M
Deferred long term liab - - - - -
Other current liab - - 1.79M 0.83M 0.89M
Common stock - - 98.26M 98.13M 77.03M
Capital stock 112.05M 109.37M 98.26M 98.13M 77.03M
Retained earnings -103.66706M -101.73024M -92.28922M -80.90939M -75.09758M
Other liab - - 0.00706M 0.00113M 0.00012M
Good will - - - - -
Other assets - - - - -
Cash 10.17M 11.87M 10.97M 19.23M 6.02M
Cash and equivalents - - - - 6.02M
Total current liabilities 2.43M 5.15M 2.81M 1.16M 1.05M
Current deferred revenue - - -0.09408M -0.09409M -0.07944M
Net debt - - -10.82516M -19.00578M -5.71356M
Short term debt - - 0.09M 0.09M 0.08M
Short long term debt - - - - -
Short long term debt total - - 0.14M 0.23M 0.31M
Other stockholder equity - - 4.00M 3.92M 3.79M
Property plant equipment - - 0.15M 0.22M 0.30M
Total current assets 12.40M 14.47M 12.69M 22.22M 6.70M
Long term investments - - - - -
Net tangible assets - - 9.98M 21.14M 5.73M
Short term investments - - 10.50M 18.42M -
Net receivables 0.06M 0.08M 1.66M 1.84M 0.60M
Long term debt - - - - -
Inventory - - 0.00000M 0.00000M 0.00000M
Accounts payable 1.43M 3.73M 1.02M 0.33M 0.16M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 4.00M 3.92M 3.79M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - -0.15079M -0.21670M -0.30200M
Deferred long term asset charges - - - - -
Non current assets total 0.04M 0.06M 0.15M 0.22M 0.30M
Capital lease obligations 0.03M 0.04M 0.14M 0.23M 0.31M
Long term debt total - - 0.05M 0.13M 0.23M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.00724M -0.00361M -0.02929M -0.00391M -0.00835M
Change to liabilities - - 1.76M 0.03M 0.22M
Total cashflows from investing activities -0.00724M -0.00361M -0.02929M -0.00391M -0.00835M
Net borrowings - - -0.08530M -0.07944M -0.08238M
Total cash from financing activities 13.95M 11.02M -0.08530M 21.02M 7.80M
Change to operating activities - - 0.77M -0.99621M 0.45M
Net income -14.92191M -11.91922M -11.37983M -5.81181M -8.06064M
Change in cash -1.69880M 0.90M -8.26592M 13.21M 1.96M
Begin period cash flow 11.87M 10.97M 19.23M 6.02M 4.06M
End period cash flow 10.17M 11.87M 10.97M 19.23M 6.02M
Total cash from operating activities -15.64331M -10.11585M -8.15133M -7.80517M -5.83416M
Issuance of capital stock 14.87M 11.61M - 22.59M 8.50M
Depreciation - - 0.10M 0.09M 0.10M
Other cashflows from investing activities - - - - -
Dividends paid - - - 0.08M 0.08M
Change to inventory - - - - -
Change to account receivables 0.97M -0.83236M 0.34M -1.23972M 0.09M
Sale purchase of stock -0.86469M -0.50328M 0.00000M -1.48520M -0.61415M
Other cashflows from financing activities -0.05505M -0.08939M -0.02929M 0.08M 0.08M
Change to netincome - - 0.26M 0.12M 1.37M
Capital expenditures 0.00724M 0.00361M 0.03M 0.00391M 0.00835M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.34710M 1.53M 0.34M -1.23972M 0.09M
Stock based compensation - - 0.21M 0.12M 1.37M
Other non cash items -13.29621M 0.28M 3.13M -2.08257M 2.12M
Free cash flow -15.65055M -10.11946M -8.18062M -7.80908M -5.84251M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PER
Percheron Therapeutics Ltd		 - -% - - 9.35 4.38 1.07 117.93 -4.4641
AFP
Aft Pharmaceuticals Ltd		 - -% 3.00 23.08 19.88 1.35 3.81 1.72 13.67
VLS
Vita Life Sciences Ltd		 -0.02 0.80% 2.48 13.89 42.73 1.46 2.42 1.24 6.53
SNT
Syntara Ltd		 -0.001 3.33% 0.03 - 20.45 6.32 4.62 6.32 -2.1607
MVP
Medical Developments International Ltd		 0.005 1.23% 0.41 - 166.67 1.14 0.83 0.75 11.48

Reports Covered

Stock Research & News

View All

Profile

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of T-cell activation and cancer cells. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Percheron Therapeutics Ltd

Collins Place, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD CEO, MD & Director NA
Mr. Phillip Allen Hains BBus(Acc), CA, MBA CFO & Joint Company Sec. 1959
Dr. George Tachas Director of Drug Discovery & Patents NA
Ms. Nuket Desem Director of Clinical and Regulatory affairs NA
Dr. Anthony Filippis Chief Commercial Officer NA
Ms. Alicia Mellors Joint Company Sec. NA
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA CEO, MD & Director 1973
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Joint Company Secretary 1959
Dr. Anthony Filippis Chief Operating Officer NA
Ms. Alicia Mellors Joint Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.